Treatment of systemic juvenile idiopathic arthritis: is the conventional approach converted?
10.3760/cma.j.issn.2095-428X.2017.09.002
- VernacularTitle:全身型幼年特发性关节炎的治疗:传统路径逆转了吗?
- Author:
Haiguo YU
- Keywords:
Systemic juvenile idiopathic arthritis;
Window of opportunity;
Cytokine inhibitor
- From:
Chinese Journal of Applied Clinical Pediatrics
2017;32(9):645-647
- CountryChina
- Language:Chinese
-
Abstract:
Systemic juvenile idiopathic arthritis (sJIA) is an inflammatory disorder characterized by fever,lymphadenopathy,arthritis,rash and serositis.In sJIA,systemic inflammation has been associated with dysregulation of the innate immune system,suggesting that it is an autoinflammatory disorder.Interleukin(IL)-1 and IL-6 play a major role in the pathogenesis of sJIA.Glucocorticoids and disease modifying anti-rheumatic drugs(DMARDS) are the conventional treatment of patients with sJIA.The major advances in the therapy of sJIA are the applications of IL-1 and IL-6 inhibitors and have shown to be highly effective.Recent data suggests that early cytokine blockage might alter the chronic arthritis course,which reflect a potential window of opportunity in the care of children with sJIA.The purpose of this article is to discuss the treatment approach of the patients with sJIA according to the recently published literature.
